BioSpace News Archive

Drug Development

Despite Threat of Omicron, World Shifts Focus Away from COVID-19

There’s quite a bit of movement on the Omicron-specific booster shot and updated supply deals, despite world leaders shifting their attention away from the COVID-19 pandemic.

June 30, 2022
·
5 min read
·
Mark Terry
Drug Development

BeiGene, Lexicon and 9 Meters Wrap First Half with Clinical Wins

Capping off the first half of the year is a flurry of clinical trial wins. BioSpace takes a look at some of the most exciting ones:

June 30, 2022
·
4 min read
·
Tristan Manalac
Research Roundup: Scientists Find Link Between COVID-19, New-Onset Diabetes

COVID-19 is much more than a respiratory illness, and many of its longer-term effects and secondary issues are often puzzling. For that and more research news, continue reading.

June 30, 2022
·
6 min read
·
Mark Terry
Business

AstraZeneca Touts China Expansion, Positive CHMP Opinions

AstraZeneca had a very busy week of international news, with progress being shown in China, positive recommendations for two drugs in Europe and a positive clinical trial update.

June 30, 2022
·
3 min read
·
Mark Terry
Business

BioSpace Movers & Shakers: Evommune, Maravai, Aptose & More

Entering the second half of 2022, biopharma and life sciences companies from across the globe strengthen their leadership teams with new additions to the c-suite.

June 30, 2022
·
5 min read
·
Alex Keown
Drug Development

Angion Ends Kidney Disease Trial while Novo Hits NASH Wall

Angion Biomedica Corp. discontinued a Phase II kidney disease trial while Novo Nordisk missed the mark in a NASH study.

June 30, 2022
·
3 min read
·
Alex Keown
Drug Development

Innate’s Cancer Therapeutics are Reaching New Clinical Heights

Many of Innate Pharma’s cancer-fighting products are making clinical progress. BioSpace spoke with the company’s head of product portfolio strategy and business development, Yannis Morel, Ph.D.

June 30, 2022
·
5 min read
·
Abbey Glasure
Business

After Layoffs, Big Companies Advance and Small Firms Retrench

After the spring reductions in the workforce that left thousands of biotech employees searching for jobs, larger companies are, for the most part, moving forward.

June 30, 2022
·
5 min read
·
Gail Dutton
Lone Star Bio

FUJIFILM Continues Cell Culture Quest, Invests $1.6B in Texas, Denmark Facilities

The $1.6-billion infusion into its subsidiary is Fujifilm’s latest move to establish a more robust presence in the cell culture manufacturing space.

June 30, 2022
·
3 min read
·
Tristan Manalac
eFFECTOR Takes Road Less Traveled to Maximize Cancer Treatment

eFFECTOR Therapeutics is pioneering the development of selective translation regulation inhibitors (STRIs), a class of therapies that block the production of disease-driving proteins in cancer. 

June 30, 2022
·
4 min read
·
Kaley Lefevre